PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

Name: PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC
Published: 2026
License: Public Domain

Guangdong Association of Clinical Trials · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

l1 pd

lung adenocarcinoma, pd-l1, ctla-4, ql1706, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

Related documents